HHLA2 表达在实体瘤中的预后价值：基于中国人群的荟萃分析。

Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population.

机构信息

The Center for Translational Medicine, Taizhou People's Hospital, Affiliated 5 to Nantong University, Taizhou, Jiangsu Province, China.

Outpatient Department, Taizhou People's Hospital, Affiliated 5 to Nantong University, Taizhou, Jiangsu Province, China.

出版信息

Medicine (Baltimore). 2021 Jul 30;100(30):e26789. doi: 10.1097/MD.0000000000026789.

DOI:10.1097/MD.0000000000026789

PMID:34397730

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8322499/

Abstract

BACKGROUND

Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), a newly discovered member of the B7 family, is overexpressed in numerous tumors. However, the prognostic impact of HHLA2 in human cancers remains controversial. Thus, we performed this meta-analysis to explore the prognostic value of HHLA2 in Chinese patients with solid tumors.

METHODS

PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure, and WanFang databases were systematically searched for eligible studies that evaluated the impact of HHLA2 on overall survival (OS) in patients with cancer. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to evaluate the association between HHLA2 expression and OS in solid tumors. Odds ratios (ORs) and 95% CIs were pooled to assess the correlation between HHLA2 expression and clinicopathological characteristics in solid tumors.

RESULTS

A total of 12 studies, including 15 cohorts and 1747 patients, were included in this meta-analysis. We found that high HHLA2 expression was significantly associated with shorter OS (HR = 1.65, 95% CI: 1.12-2.43). Subgroup analysis by cancer type demonstrated that high HHLA2 expression was associated with poor OS in patients with clear cell renal cell carcinoma (HR = 3.42, 95% CI: 2.39-4.91), gastric cancer (HR = 2.03, 95% CI: 1.31-3.16), intrahepatic cholangiocarcinoma (HR = 1.77, 95% CI: 1.24-2.53), lung cancer (HR = 2.14, 95% CI: 1.33-3.44) and other cancer types (HR = 2.08, 95% CI: 1.34-3.24), but not in patients with epithelial ovarian cancer (HR = 0.52, 95% CI: 0.08-3.56). Nevertheless, high HHLA2 expression was associated with better OS in patients with pancreatic ductal adenocarcinoma (HR = 0.45, 95% CI: 0.32-0.64). Furthermore, high HHLA2 expression was associated with old age (OR = 1.30, 95% CI: 1.03-1.63), lymph node metastasis (OR = 1.99, 95% CI: 1.41-2.81), and vascular invasion (OR = 1.69, 95% CI: 1.18-2.42).

CONCLUSIONS

HHLA2 may serve as a potential prognostic biomarker for solid tumors in Chinese population, by predict the prognosis of cancer patients based on their tumor types.

摘要

背景

人类内源性逆转录病毒-H 长末端重复相关蛋白 2（HHLA2）是 B7 家族的新发现成员，在许多肿瘤中过度表达。然而，HHLA2 在人类癌症中的预后影响仍存在争议。因此，我们进行了这项荟萃分析，以探讨 HHLA2 在中国人实体瘤中的预后价值。

方法

系统检索 PubMed、Embase、Web of Science、中国知网和万方数据库，以评估 HHLA2 对癌症患者总生存期（OS）的影响。使用风险比（HR）和 95%置信区间（CI）合并来评估 HHLA2 表达与实体瘤 OS 之间的关联。使用优势比（OR）和 95%CI 合并来评估 HHLA2 表达与实体瘤临床病理特征之间的相关性。

结果

本荟萃分析共纳入 12 项研究，包括 15 个队列和 1747 名患者。我们发现，HHLA2 高表达与较短的 OS 显著相关（HR=1.65，95%CI：1.12-2.43）。按癌症类型进行的亚组分析表明，HHLA2 高表达与透明细胞肾细胞癌（HR=3.42，95%CI：2.39-4.91）、胃癌（HR=2.03，95%CI：1.31-3.16）、肝内胆管癌（HR=1.77，95%CI：1.24-2.53）、肺癌（HR=2.14，95%CI：1.33-3.44）和其他癌症类型（HR=2.08，95%CI：1.34-3.24）患者的 OS 较差相关，但与上皮性卵巢癌（HR=0.52，95%CI：0.08-3.56）患者的 OS 无关。然而，HHLA2 高表达与胰腺导管腺癌（HR=0.45，95%CI：0.32-0.64）患者的 OS 较好相关。此外，HHLA2 高表达与老年（OR=1.30，95%CI：1.03-1.63）、淋巴结转移（OR=1.99，95%CI：1.41-2.81）和血管侵犯（OR=1.69，95%CI：1.18-2.42）相关。